Welcome to our dedicated page for Briacell Therapeutics news (Ticker: BCTX), a resource for investors and traders seeking the latest updates and insights on Briacell Therapeutics stock.
BriaCell Therapeutics Corp. (BCTX) generates frequent news flow as a clinical-stage biotechnology company developing novel immunotherapies for cancer, with a strong focus on metastatic breast cancer. News about BriaCell often centers on clinical trial milestones, emerging efficacy and safety data, biomarker analyses, and platform advancements across its Bria-IMT™, Bria-OTS™, and Bria-OTS+™ programs.
Investors and researchers following BCTX news can track updates on the pivotal Phase 3 Bria-IMT trial in advanced metastatic breast cancer, including enrollment progress, interim analyses, and presentations at major scientific meetings such as the San Antonio Breast Cancer Symposium (SABCS®). Company releases describe survival outcomes, progression-free survival signals, and potential predictive biomarkers like neutrophil-to-lymphocyte ratio, delayed-type hypersensitivity responses, and Th1-biased cytokine signatures.
BriaCell’s news stream also highlights developments in its Bria-OTS and Bria-OTS+ off-the-shelf immunotherapy platforms. Announcements include clinical observations such as sustained complete resolution of lung metastasis in a metastatic breast cancer patient treated with Bria-OTS, as well as preclinical data showing robust innate and adaptive immune activation by Bria-OTS+ candidates Bria-BRES+™ and Bria-PROS+™ in breast and prostate cancer models.
Additional coverage includes corporate and pipeline updates from BriaPro Therapeutics Corp., BriaCell’s subsidiary, and its AI-driven collaboration with Receptor.AI to design isoform-selective kinase inhibitors. For those monitoring BCTX, this news page provides a centralized view of regulatory designations, trial recognitions in scientific publications, collaborative research announcements, and detailed scientific poster summaries. Regular visits can help readers follow how BriaCell’s immunotherapy platforms evolve from preclinical research through late-stage clinical evaluation.
BriaCell (Nasdaq: BCTX) announced six clinical data items at the 2026 ASCO Annual Meeting (May 29–June 2, 2026): three poster presentations and three publication-only abstracts covering survival, quality of life, biomarkers, and cell‑based immunotherapy in metastatic breast cancer.
Poster sessions occur May 30 and June 1, 2026; ASCO will publish abstracts May 21, 2026 at 5:00 PM ET. Poster copies will be posted at https://briacell.com/scientific-publications/ after presentation.
BriaCell (Nasdaq: BCTX) presented preclinical data for its Bria-OTS+ engineered whole-cell immunotherapy at AACR 2026 showing rapid activation of innate and adaptive immunity, durable cytokine responses, and sustained serial tumor-cell killing across breast and prostate models.
The company said Bria-OTS+ activated CD4+, CD8+, NK, NKT, dendritic and B cells, limited Treg and MDSC induction, demonstrated cross-tumor recognition, and plans to advance into clinical testing for metastatic breast and prostate cancer later in 2026.
BriaCell (Nasdaq: BCTX) presented Phase 3 quality-of-life and Phase 2 biomarker findings at AACR 2026 on April 20–21. The Phase 3 Bria-IMT + CPI data show QOL largely preserved in heavily pretreated metastatic breast cancer patients with prior ADC, CPI, and CDK4/6 exposure.
Phase 2 analyses identify mitotic circulating tumor cells as a potential prognostic biomarker and PD-L1 in tumor-macrophage fusion cells as a blood-based predictor of checkpoint inhibitor benefit. Posters and abstracts are available through the company.
BriaCell (Nasdaq: BCTX) reported an 11-month sustained complete resolution of a lung metastasis in the first patient enrolled in the Bria-OTS Phase 1/2a metastatic breast cancer study.
The 78-year-old hormone receptor-positive, HER2-negative patient achieved 100% resolution after four doses of Bria-OTS monotherapy, with the response first seen at 2 months and confirmed at 4, 6, and 11 months; the patient completed 12 months on study, received 17 cycles, reported no treatment-limiting toxicities, maintained stable disease at other evaluable sites, and remains in survival follow-up.
The Phase 1 dose-escalation is complete and the Phase 2a combination study with an immune checkpoint inhibitor is underway.
BriaCell (Nasdaq: BCTX) announced its Phase 3 Bria-IMT trial in metastatic breast cancer (BRIA-ABC) was highlighted in Nature Medicine’s "Eleven clinical trials that will shape medicine in 2026."
The company said the trial has screened more than 230 patients and enrolled over 160 patients, with an interim analysis scheduled once 144 patient events (deaths) occur. BriaCell anticipates reporting topline data as early as H1-2026. The Bria-IMT combination has FDA Fast Track designation. The primary endpoint at interim is overall survival comparing Bria-IMT plus checkpoint inhibitor versus physician’s choice.
BriaCell (Nasdaq: BCTX) presented Phase 2 survival and Phase 3 biomarker data across three posters at SABCS® 2025 (Dec 9-12, 2025). A pooled interim analysis (116 patients) from the Bria-ABC Phase 3 trial showed a favorable safety profile with no treatment-related discontinuations, early PFS signals by subtype (median PFS: HR+/HER2- 3.7 months; HER2-Low 3.9 months) and a potential predictive Neutrophil-to-Lymphocyte Ratio (NLR) signal (favorable NLR 0.7–2.3: PFS 4.4 vs 2.6 months). Phase 2 data (n=54) reported DTH+ patients with higher median OS (11.3 vs 4.7 months, P=0.0001) and Th1-biased cytokine signatures correlated with clinical benefit in biomarker analyses (n=30). Further analysis planned as enrollment and OS mature.
BriaCell (Nasdaq: BCTX) reported that its pivotal Phase 3 study in metastatic breast cancer has screened >230 patients and enrolled >160, with enrollment exceeding expectations and strong site/patient interest.
The company expects a topline interim data readout as early as 1H2026; the interim analysis will occur once 144 patient events (deaths) are observed and will assess overall survival (OS) versus physician’s choice. The Phase 3 regimen retains FDA Fast Track designation and positive results could support full approval and marketing authorization for Bria-IMT.
BriaCell (Nasdaq: BCTX) will present three posters at the San Antonio Breast Cancer Symposium (SABCS) on December 10, 2025, reporting positive Phase 2 survival and Phase 3 biomarker data.
A pooled interim analysis of 116 patients with MHC subtyping in the ongoing pivotal Phase 3 showed an excellent safety profile, improved PFS in HR+/HER2- and HER2-low subtypes, and NLR as a potential biomarker. Phase 1/2 data in 54 metastatic breast cancer patients reported continued overall survival benefit and DTH as a possible predictive biomarker. Cytokine analysis of 30 patients suggests Th1-biased signatures may predict response. An interim Phase 3 analysis is expected in 1H2026.
BriaCell (Nasdaq: BCTX) will present three posters at the San Antonio Breast Cancer Symposium on December 10, 2025 highlighting positive Phase 2 safety and efficacy signals, positive biomarker findings, and survival data.
The company said its pivotal Phase 3 Bria-IMT+CPI trial is ongoing with an interim analysis expected in H1 2026. The Bria-IMT regimen has received Fast Track designation from the US FDA. Abstract and poster copies will be available on the company's scientific publications webpage.
BriaCell (Nasdaq: BCTX) announced that its subsidiary BriaPro initiated a research collaboration with Receptor.AI on Nov. 20, 2025 to design isoform-selective small-molecule kinase inhibitors for multiple cancer indications.
The partnership will combine Receptor.AI's AI-driven small-molecule discovery platform for target assessment, hit identification, and lead optimization with BriaPro's proprietary technology to expand BriaPro's small-molecule pipeline and aim to accelerate development of kinase inhibitors with improved selectivity, ADMET constraints, and potential to enhance immune-mediated tumor targeting.